...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology.
【24h】

Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology.

机译：静脉注射免疫球蛋白和辅助疗法在原发性免疫缺陷治疗中的应用：美国过敏性哮喘和免疫科学院原发性免疫缺陷委员会的工作组报告和研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

There are an expanding number of primary immunodeficiency diseases (PIDDs), each associated with unique diagnostic and therapeutic complexities. Limited data, however, exist supporting specific therapeutic interventions. Thus, a survey of PIDD management was administered to allergists/immunologists in the United States to identify current perspectives and practices. Among 405 respondents, the majority of key management practices identified were consistent with existing data and guidelines, including the provision of immunoglobulin therapy, immunoglobulin dosing and selective avoidance of live viral vaccines. Practices for which there are little specific data or evidence-based guidance were also examined, including evaluation of IgG trough levels for patients receiving immunoglobulin, use of prophylactic antibiotics and recommendations for complementary/alternative medicine. Here, variability applied to PIDD patients was identified. Differences between practitioners clinically focused upon PIDD and general allergists/immunologists were also identified. Thus, a need for expanded clinical research in PIDD to optimize management and potentially improve outcomes was defined.
机译：越来越多的原发性免疫缺陷疾病（PIDDs），每种疾病都与独特的诊断和治疗复杂性有关。然而，有限的数据支持特定的治疗干预措施。因此，对美国的过敏症专家/免疫学家进行了PIDD管理调查，以确定当前的观点和做法。在405位受访者中，确定的大多数关键管理措施与现有数据和指南一致，包括提供免疫球蛋白治疗，免疫球蛋白剂量和选择性避免活病毒疫苗。还检查了几乎没有具体数据或循证指南的实践，包括评估接受免疫球蛋白的患者的IgG谷水平，使用预防性抗生素以及推荐使用补充/替代药物。在此，确定了应用于PIDD患者的变异性。还确定了临床上专注于PIDD的从业者与普通过敏症/免疫学家之间的差异。因此，定义了在PIDD中扩展临床研究以优化管理并潜在改善结果的需求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号